SK283075B6 - Deriváty 4-oxo-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamidu a farmaceutický prostriedok, ktorý ich obsahuje - Google Patents
Deriváty 4-oxo-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamidu a farmaceutický prostriedok, ktorý ich obsahuje Download PDFInfo
- Publication number
- SK283075B6 SK283075B6 SK129-2000A SK1292000A SK283075B6 SK 283075 B6 SK283075 B6 SK 283075B6 SK 1292000 A SK1292000 A SK 1292000A SK 283075 B6 SK283075 B6 SK 283075B6
- Authority
- SK
- Slovakia
- Prior art keywords
- mmol
- dihydro
- pyridazino
- methyl
- indole
- Prior art date
Links
- QYGVTWDMEAZITC-UHFFFAOYSA-N 2-(4-oxo-3,5-dihydropyridazino[4,5-b]indol-1-yl)acetamide Chemical class N1C2=CC=CC=C2C2=C1C(=O)NN=C2CC(=O)N QYGVTWDMEAZITC-UHFFFAOYSA-N 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 3
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims abstract description 26
- -1 phenylmethoxy group Chemical group 0.000 claims abstract description 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 12
- 125000002393 azetidinyl group Chemical group 0.000 claims abstract description 7
- 125000005843 halogen group Chemical group 0.000 claims abstract description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims abstract description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000005936 piperidyl group Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 83
- 239000001257 hydrogen Substances 0.000 abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000007428 synaptic transmission, GABAergic Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 102
- 239000000203 mixture Substances 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
- 239000000243 solution Substances 0.000 description 52
- 239000007787 solid Substances 0.000 description 45
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 238000010992 reflux Methods 0.000 description 31
- 239000000047 product Substances 0.000 description 30
- 238000001914 filtration Methods 0.000 description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 239000002904 solvent Substances 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 239000002244 precipitate Substances 0.000 description 21
- 125000001309 chloro group Chemical group Cl* 0.000 description 20
- 239000012074 organic phase Substances 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 15
- 229960000583 acetic acid Drugs 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 11
- 235000011152 sodium sulphate Nutrition 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 8
- 229940067157 phenylhydrazine Drugs 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229960004381 flumazenil Drugs 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 230000000949 anxiolytic effect Effects 0.000 description 4
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- AIZUWNQXNBXSFP-UHFFFAOYSA-N 2-(5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetic acid Chemical compound O=C1C=2N(C)C3=CC=CC=C3C=2C(CC(O)=O)=NN1C1=CC=CC=C1 AIZUWNQXNBXSFP-UHFFFAOYSA-N 0.000 description 3
- NGTQLLKQKAUYMI-UHFFFAOYSA-N 2-(8-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetic acid Chemical compound O=C1C=2N(C)C3=CC=C(Cl)C=C3C=2C(CC(O)=O)=NN1C1=CC=CC=C1 NGTQLLKQKAUYMI-UHFFFAOYSA-N 0.000 description 3
- XKIRNYLZSARPBF-UHFFFAOYSA-N 2-(9-bromo-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetic acid Chemical compound O=C1C=2N(C)C3=CC=CC(Br)=C3C=2C(CC(O)=O)=NN1C1=CC=CC=C1 XKIRNYLZSARPBF-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 125000003158 alcohol group Chemical group 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 150000005690 diesters Chemical class 0.000 description 3
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 3
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 3
- SRUOLCVDPWORFN-UHFFFAOYSA-N 1-(bromomethyl)-5-ethyl-8-fluoro-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(CC)C3=CC=C(F)C=C3C=2C(CBr)=NN1C1=CC=CC=C1 SRUOLCVDPWORFN-UHFFFAOYSA-N 0.000 description 2
- AIHUBJRDRLESCF-UHFFFAOYSA-N 1-(bromomethyl)-8-fluoro-5-(methoxymethyl)-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(COC)C3=CC=C(F)C=C3C=2C(CBr)=NN1C1=CC=CC=C1 AIHUBJRDRLESCF-UHFFFAOYSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- HECHENSCQYUBHZ-UHFFFAOYSA-N 2-(5,8-dimethyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)-n,n-dimethylacetamide Chemical compound O=C1C=2N(C)C3=CC=C(C)C=C3C=2C(CC(=O)N(C)C)=NN1C1=CC=CC=C1 HECHENSCQYUBHZ-UHFFFAOYSA-N 0.000 description 2
- ZNXISFSKCMPYIL-UHFFFAOYSA-N 2-(5,8-dimethyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetonitrile Chemical compound C12=CC(C)=CC=C2N(C)C(C2=O)=C1C(CC#N)=NN2C1=CC=CC=C1 ZNXISFSKCMPYIL-UHFFFAOYSA-N 0.000 description 2
- DZZZGQHDTKHZAL-UHFFFAOYSA-N 2-(5-ethyl-8-fluoro-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)-n,n-dimethylacetamide Chemical compound O=C1C=2N(CC)C3=CC=C(F)C=C3C=2C(CC(=O)N(C)C)=NN1C1=CC=CC=C1 DZZZGQHDTKHZAL-UHFFFAOYSA-N 0.000 description 2
- SHDYVPKEQTWDQE-UHFFFAOYSA-N 2-(5-ethyl-8-fluoro-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetic acid Chemical compound O=C1C=2N(CC)C3=CC=C(F)C=C3C=2C(CC(O)=O)=NN1C1=CC=CC=C1 SHDYVPKEQTWDQE-UHFFFAOYSA-N 0.000 description 2
- CCRKQAZAOJLVKW-UHFFFAOYSA-N 2-(5-ethyl-8-fluoro-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetonitrile Chemical compound O=C1C=2N(CC)C3=CC=C(F)C=C3C=2C(CC#N)=NN1C1=CC=CC=C1 CCRKQAZAOJLVKW-UHFFFAOYSA-N 0.000 description 2
- IVAXNAPQNKKHNX-UHFFFAOYSA-N 2-(7-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)-n,n-diethylacetamide Chemical compound O=C1C=2N(C)C3=CC(Cl)=CC=C3C=2C(CC(=O)N(CC)CC)=NN1C1=CC=CC=C1 IVAXNAPQNKKHNX-UHFFFAOYSA-N 0.000 description 2
- XKNQLOVDKJOJCA-UHFFFAOYSA-N 2-(7-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetonitrile Chemical compound O=C1C=2N(C)C3=CC(Cl)=CC=C3C=2C(CC#N)=NN1C1=CC=CC=C1 XKNQLOVDKJOJCA-UHFFFAOYSA-N 0.000 description 2
- AFGDZGKETASTNL-UHFFFAOYSA-N 2-(8-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetonitrile Chemical compound O=C1C=2N(C)C3=CC=C(Cl)C=C3C=2C(CC#N)=NN1C1=CC=CC=C1 AFGDZGKETASTNL-UHFFFAOYSA-N 0.000 description 2
- YCBJPRYHHFSCRH-UHFFFAOYSA-N 2-(8-fluoro-4-oxo-3-phenyl-5H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide Chemical compound CN(C)C(=O)Cc1nn(-c2ccccc2)c(=O)c2[nH]c3ccc(F)cc3c12 YCBJPRYHHFSCRH-UHFFFAOYSA-N 0.000 description 2
- HXKGNDPKXMSGMT-UHFFFAOYSA-N 2-(9-bromo-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetonitrile Chemical compound O=C1C=2N(C)C3=CC=CC(Br)=C3C=2C(CC#N)=NN1C1=CC=CC=C1 HXKGNDPKXMSGMT-UHFFFAOYSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- WKNOKWQTCZFTLM-UHFFFAOYSA-N 2-[8-fluoro-5-(methoxymethyl)-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl]acetonitrile Chemical compound O=C1C=2N(COC)C3=CC=C(F)C=C3C=2C(CC#N)=NN1C1=CC=CC=C1 WKNOKWQTCZFTLM-UHFFFAOYSA-N 0.000 description 2
- BRMAFUSPPQZPBT-UHFFFAOYSA-N 9-bromo-1,5-dimethyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(C)C3=CC=CC(Br)=C3C=2C(C)=NN1C1=CC=CC=C1 BRMAFUSPPQZPBT-UHFFFAOYSA-N 0.000 description 2
- XQZYRONQCQPFCC-UHFFFAOYSA-N 9-bromo-1-(bromomethyl)-5-methyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(C)C3=CC=CC(Br)=C3C=2C(CBr)=NN1C1=CC=CC=C1 XQZYRONQCQPFCC-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010053398 Clonic convulsion Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000012455 biphasic mixture Substances 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- DFGMZWFTGORNFX-UHFFFAOYSA-N ethyl 1-ethyl-5-fluoro-3-(2-methoxy-2-oxoacetyl)indole-2-carboxylate Chemical compound FC1=CC=C2N(CC)C(C(=O)OCC)=C(C(=O)C(=O)OC)C2=C1 DFGMZWFTGORNFX-UHFFFAOYSA-N 0.000 description 2
- HNQSPSRSXQCGGV-UHFFFAOYSA-N ethyl 5-chloro-3-(2-methoxy-2-oxoacetyl)-1-methylindole-2-carboxylate Chemical compound ClC1=CC=C2N(C)C(C(=O)OCC)=C(C(=O)C(=O)OC)C2=C1 HNQSPSRSXQCGGV-UHFFFAOYSA-N 0.000 description 2
- VIKOQTQMWBKMNA-UHFFFAOYSA-N ethyl 5-fluoro-1h-indole-2-carboxylate Chemical compound FC1=CC=C2NC(C(=O)OCC)=CC2=C1 VIKOQTQMWBKMNA-UHFFFAOYSA-N 0.000 description 2
- QMVJTCIUKISOGR-UHFFFAOYSA-N ethyl 6-chloro-1-methylindole-2-carboxylate Chemical compound C1=C(Cl)C=C2N(C)C(C(=O)OCC)=CC2=C1 QMVJTCIUKISOGR-UHFFFAOYSA-N 0.000 description 2
- UOBUAOPQJRUMIS-UHFFFAOYSA-N ethyl 8-fluoro-4-oxo-3-phenyl-5H-pyridazino[4,5-b]indole-1-carboxylate Chemical compound FC1=CC=2C3=C(NC2C=C1)C(N(N=C3C(=O)OCC)C3=CC=CC=C3)=O UOBUAOPQJRUMIS-UHFFFAOYSA-N 0.000 description 2
- YPIJONONGVJKOI-UHFFFAOYSA-N ethyl 8-fluoro-5-(methoxymethyl)-4-oxo-3-phenylpyridazino[4,5-b]indole-1-carboxylate Chemical compound O=C1C=2N(COC)C3=CC=C(F)C=C3C=2C(C(=O)OCC)=NN1C1=CC=CC=C1 YPIJONONGVJKOI-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- KCKIKSJECTZLJA-UHFFFAOYSA-N indol-4-one Chemical compound O=C1C=CC=C2N=CC=C12 KCKIKSJECTZLJA-UHFFFAOYSA-N 0.000 description 2
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- CINPLCMEILSUTJ-UHFFFAOYSA-N methyl 2-azido-3-(2-bromophenyl)prop-2-enoate Chemical compound COC(=O)C(N=[N+]=[N-])=CC1=CC=CC=C1Br CINPLCMEILSUTJ-UHFFFAOYSA-N 0.000 description 2
- NIIZOBJLUXKGRH-UHFFFAOYSA-N methyl 3-acetyl-4-bromo-1-methylindole-2-carboxylate Chemical compound C1=CC=C2N(C)C(C(=O)OC)=C(C(C)=O)C2=C1Br NIIZOBJLUXKGRH-UHFFFAOYSA-N 0.000 description 2
- DTPOJMDJBBGYFK-UHFFFAOYSA-N methyl 4-bromo-1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OC)=CC2=C1Br DTPOJMDJBBGYFK-UHFFFAOYSA-N 0.000 description 2
- FFELLMINXHHZFW-UHFFFAOYSA-N methyl 5-ethyl-8-fluoro-4-oxo-3-phenylpyridazino[4,5-b]indole-1-carboxylate Chemical compound O=C1C=2N(CC)C3=CC=C(F)C=C3C=2C(C(=O)OC)=NN1C1=CC=CC=C1 FFELLMINXHHZFW-UHFFFAOYSA-N 0.000 description 2
- IZITWQUNZSRMSQ-UHFFFAOYSA-N methyl 8-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indole-1-carboxylate Chemical compound O=C1C=2N(C)C3=CC=C(Cl)C=C3C=2C(C(=O)OC)=NN1C1=CC=CC=C1 IZITWQUNZSRMSQ-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- MCLGZNGDLWVKKA-UHFFFAOYSA-N n,n-dimethyl-2-(5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetamide Chemical compound O=C1C=2N(C)C3=CC=CC=C3C=2C(CC(=O)N(C)C)=NN1C1=CC=CC=C1 MCLGZNGDLWVKKA-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 150000003334 secondary amides Chemical class 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003511 tertiary amides Chemical class 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 2
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- QYAPHLRPFNSDNH-MRFRVZCGSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O QYAPHLRPFNSDNH-MRFRVZCGSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- FYIYGLQUOXPNJH-UHFFFAOYSA-N 1-(bromomethyl)-8-chloro-5-methyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(C)C3=CC=C(Cl)C=C3C=2C(CBr)=NN1C1=CC=CC=C1 FYIYGLQUOXPNJH-UHFFFAOYSA-N 0.000 description 1
- MTOCNSSVLMHZSL-UHFFFAOYSA-N 1-(chloromethyl)-5,8-dimethyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound C12=CC(C)=CC=C2N(C)C(C2=O)=C1C(CCl)=NN2C1=CC=CC=C1 MTOCNSSVLMHZSL-UHFFFAOYSA-N 0.000 description 1
- BPWDOIOAEBSMEI-UHFFFAOYSA-N 1-(hydroxymethyl)-5,8-dimethyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound C12=CC(C)=CC=C2N(C)C(C2=O)=C1C(CO)=NN2C1=CC=CC=C1 BPWDOIOAEBSMEI-UHFFFAOYSA-N 0.000 description 1
- UEFGLENGHNNEBY-UHFFFAOYSA-N 1-methoxyethanol hydrate Chemical compound O.COC(C)O UEFGLENGHNNEBY-UHFFFAOYSA-N 0.000 description 1
- DWLVFWDCSFTDOD-UHFFFAOYSA-N 2-(1h-indol-3-yl)-2-oxoacetic acid Chemical compound C1=CC=C2C(C(=O)C(=O)O)=CNC2=C1 DWLVFWDCSFTDOD-UHFFFAOYSA-N 0.000 description 1
- YZLXFDAHJQYGHP-UHFFFAOYSA-N 2-(5,8-dimethyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetic acid Chemical compound C12=CC(C)=CC=C2N(C)C(C2=O)=C1C(CC(O)=O)=NN2C1=CC=CC=C1 YZLXFDAHJQYGHP-UHFFFAOYSA-N 0.000 description 1
- NYMOTNIJLGLDHN-UHFFFAOYSA-N 2-(5-methyl-4-oxo-3-phenyl-8-phenylmethoxypyridazino[4,5-b]indol-1-yl)acetic acid Chemical compound C1=C2C=3C(CC(O)=O)=NN(C=4C=CC=CC=4)C(=O)C=3N(C)C2=CC=C1OCC1=CC=CC=C1 NYMOTNIJLGLDHN-UHFFFAOYSA-N 0.000 description 1
- WNTMLIQMCCQQLR-UHFFFAOYSA-N 2-(8-fluoro-4-oxo-3-phenyl-5H-pyridazino[4,5-b]indol-1-yl)acetic acid Chemical compound OC(=O)Cc1nn(-c2ccccc2)c(=O)c2[nH]c3ccc(F)cc3c12 WNTMLIQMCCQQLR-UHFFFAOYSA-N 0.000 description 1
- YXGPTVAQYCZIBN-UHFFFAOYSA-N 2-(9-bromo-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)-n-methylacetamide Chemical compound O=C1C=2N(C)C3=CC=CC(Br)=C3C=2C(CC(=O)NC)=NN1C1=CC=CC=C1 YXGPTVAQYCZIBN-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NDOPHXWIAZIXPR-UHFFFAOYSA-N 2-bromobenzaldehyde Chemical compound BrC1=CC=CC=C1C=O NDOPHXWIAZIXPR-UHFFFAOYSA-N 0.000 description 1
- DEBMMRJSRWYGGA-UHFFFAOYSA-N 4-bromo-1-methylindole-2-carboxylic acid Chemical compound C1=CC=C2N(C)C(C(O)=O)=CC2=C1Br DEBMMRJSRWYGGA-UHFFFAOYSA-N 0.000 description 1
- HJIIDZAZBHFECW-UHFFFAOYSA-N 5-methyl-1-(2-oxo-2-pyrrolidin-1-ylethyl)-3-phenyl-8-phenylmethoxypyridazino[4,5-b]indol-4-one Chemical compound C1=C2C=3C(CC(=O)N4CCCC4)=NN(C=4C=CC=CC=4)C(=O)C=3N(C)C2=CC=C1OCC1=CC=CC=C1 HJIIDZAZBHFECW-UHFFFAOYSA-N 0.000 description 1
- URUIZLQLWKNJGV-UHFFFAOYSA-N 7-chloro-1-(hydroxymethyl)-5-methyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(C)C3=CC(Cl)=CC=C3C=2C(CO)=NN1C1=CC=CC=C1 URUIZLQLWKNJGV-UHFFFAOYSA-N 0.000 description 1
- KUSUYSHAZYRLMM-UHFFFAOYSA-N 7-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indole-1-carbaldehyde Chemical compound O=C1C=2N(C)C3=CC(Cl)=CC=C3C=2C(C=O)=NN1C1=CC=CC=C1 KUSUYSHAZYRLMM-UHFFFAOYSA-N 0.000 description 1
- CAFYGGQVXCLTCG-UHFFFAOYSA-N 8-chloro-1-(hydroxymethyl)-5-methyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(C)C3=CC=C(Cl)C=C3C=2C(CO)=NN1C1=CC=CC=C1 CAFYGGQVXCLTCG-UHFFFAOYSA-N 0.000 description 1
- CAEBDSZCRVKXBJ-UHFFFAOYSA-N 8-chloro-5-methyl-1-(2-oxo-2-pyrrolidin-1-ylethyl)-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound N=1N(C=2C=CC=CC=2)C(=O)C=2N(C)C3=CC=C(Cl)C=C3C=2C=1CC(=O)N1CCCC1 CAEBDSZCRVKXBJ-UHFFFAOYSA-N 0.000 description 1
- NOMQDNNEHXUVRB-UHFFFAOYSA-N 8-fluoro-1-(hydroxymethyl)-5-(methoxymethyl)-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound O=C1C=2N(COC)C3=CC=C(F)C=C3C=2C(CO)=NN1C1=CC=CC=C1 NOMQDNNEHXUVRB-UHFFFAOYSA-N 0.000 description 1
- DPMQMIJSGBQYIF-UHFFFAOYSA-N 9-bromo-5-methyl-1-(2-oxo-2-pyrrolidin-1-ylethyl)-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound N=1N(C=2C=CC=CC=2)C(=O)C=2N(C)C3=CC=CC(Br)=C3C=2C=1CC(=O)N1CCCC1 DPMQMIJSGBQYIF-UHFFFAOYSA-N 0.000 description 1
- PNCGJYGQSZVXEP-UHFFFAOYSA-N 9-bromo-5-methyl-3-phenylpyridazino[4,5-b]indol-4-one Chemical compound BrC=1C=2C3=C(N(C2C=CC1)C)C(N(N=C3)C3=CC=CC=C3)=O PNCGJYGQSZVXEP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- XBSUIDNGONVWEL-UHFFFAOYSA-N C(C)N1C2=C(C=3C=C(C=CC13)F)C=NN(C2=O)C2=C(C=CC=C2)CO Chemical compound C(C)N1C2=C(C=3C=C(C=CC13)F)C=NN(C2=O)C2=C(C=CC=C2)CO XBSUIDNGONVWEL-UHFFFAOYSA-N 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- XUFWGPKRTSQHEO-UHFFFAOYSA-N ClCC1=NNC(C=2N(C=3C=CC(=C(C3C21)C2=CC=CC=C2)C)C)=O Chemical compound ClCC1=NNC(C=2N(C=3C=CC(=C(C3C21)C2=CC=CC=C2)C)C)=O XUFWGPKRTSQHEO-UHFFFAOYSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007350 electrophilic reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- UGCPBPJTNIDYCS-UHFFFAOYSA-N ethyl 1-ethyl-5-fluoroindole-2-carboxylate Chemical compound FC1=CC=C2N(CC)C(C(=O)OCC)=CC2=C1 UGCPBPJTNIDYCS-UHFFFAOYSA-N 0.000 description 1
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 1
- CVNBHZZQKTYQBE-UHFFFAOYSA-N ethyl 3-(2-ethoxy-2-oxoacetyl)-5-fluoro-1h-indole-2-carboxylate Chemical compound C1=C(F)C=C2C(C(=O)C(=O)OCC)=C(C(=O)OCC)NC2=C1 CVNBHZZQKTYQBE-UHFFFAOYSA-N 0.000 description 1
- GECRCAVZSPCTDM-UHFFFAOYSA-N ethyl 5-chloro-1-methylindole-2-carboxylate Chemical compound ClC1=CC=C2N(C)C(C(=O)OCC)=CC2=C1 GECRCAVZSPCTDM-UHFFFAOYSA-N 0.000 description 1
- FSMZLIBWSAMADK-UHFFFAOYSA-N ethyl 6-chloro-1h-indole-2-carboxylate Chemical compound C1=C(Cl)C=C2NC(C(=O)OCC)=CC2=C1 FSMZLIBWSAMADK-UHFFFAOYSA-N 0.000 description 1
- YAIVDGZDNCFDNH-UHFFFAOYSA-N ethyl 6-chloro-3-(2-ethoxy-2-oxoacetyl)-1-methylindole-2-carboxylate Chemical compound ClC1=CC=C2C(C(=O)C(=O)OCC)=C(C(=O)OCC)N(C)C2=C1 YAIVDGZDNCFDNH-UHFFFAOYSA-N 0.000 description 1
- JJCGYLAKDUJYLK-UHFFFAOYSA-N ethyl 7-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indole-1-carboxylate Chemical compound O=C1C=2N(C)C3=CC(Cl)=CC=C3C=2C(C(=O)OCC)=NN1C1=CC=CC=C1 JJCGYLAKDUJYLK-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- WQJFIWXYPKYBTO-UHFFFAOYSA-N indole-1-acetic acid Chemical compound C1=CC=C2N(CC(=O)O)C=CC2=C1 WQJFIWXYPKYBTO-UHFFFAOYSA-N 0.000 description 1
- 239000003617 indole-3-acetic acid Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- PAALEOQOHSOLGW-UHFFFAOYSA-N methyl 2-(7-chloro-5-methyl-4-oxo-3-phenylpyridazino[4,5-b]indol-1-yl)acetate Chemical compound O=C1C=2N(C)C3=CC(Cl)=CC=C3C=2C(CC(=O)OC)=NN1C1=CC=CC=C1 PAALEOQOHSOLGW-UHFFFAOYSA-N 0.000 description 1
- RXYCUKSOYJWGPE-UHFFFAOYSA-N methyl 2-azidoacetate Chemical compound COC(=O)CN=[N+]=[N-] RXYCUKSOYJWGPE-UHFFFAOYSA-N 0.000 description 1
- OIMNSVYNDCDFHZ-UHFFFAOYSA-N methyl 4-bromo-1-methylindole-2-carboxylate Chemical compound C1=CC=C2N(C)C(C(=O)OC)=CC2=C1Br OIMNSVYNDCDFHZ-UHFFFAOYSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- QYZFTMMPKCOTAN-UHFFFAOYSA-N n-[2-(2-hydroxyethylamino)ethyl]-2-[[1-[2-(2-hydroxyethylamino)ethylamino]-2-methyl-1-oxopropan-2-yl]diazenyl]-2-methylpropanamide Chemical compound OCCNCCNC(=O)C(C)(C)N=NC(C)(C)C(=O)NCCNCCO QYZFTMMPKCOTAN-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9709692A FR2766823B1 (fr) | 1997-07-30 | 1997-07-30 | Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique |
| PCT/FR1998/001667 WO1999006406A1 (fr) | 1997-07-30 | 1998-07-28 | DERIVES DE 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b] INDOLE-1-ACETAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK1292000A3 SK1292000A3 (en) | 2000-08-14 |
| SK283075B6 true SK283075B6 (sk) | 2003-02-04 |
Family
ID=9509801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK129-2000A SK283075B6 (sk) | 1997-07-30 | 1998-07-28 | Deriváty 4-oxo-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamidu a farmaceutický prostriedok, ktorý ich obsahuje |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6262045B1 (cs) |
| EP (1) | EP1000063B1 (cs) |
| JP (1) | JP4322421B2 (cs) |
| KR (1) | KR100497782B1 (cs) |
| CN (1) | CN1134440C (cs) |
| AR (1) | AR013264A1 (cs) |
| AT (1) | ATE226584T1 (cs) |
| AU (1) | AU736600B2 (cs) |
| BG (1) | BG64283B1 (cs) |
| BR (1) | BR9811582B1 (cs) |
| CA (1) | CA2298522C (cs) |
| CO (1) | CO5210883A1 (cs) |
| CZ (1) | CZ290011B6 (cs) |
| DE (1) | DE69808921T2 (cs) |
| DK (1) | DK1000063T3 (cs) |
| EE (1) | EE04317B1 (cs) |
| ES (1) | ES2186212T3 (cs) |
| FR (1) | FR2766823B1 (cs) |
| HU (1) | HU229430B1 (cs) |
| IL (1) | IL133633A (cs) |
| NO (1) | NO313963B1 (cs) |
| NZ (1) | NZ502361A (cs) |
| PL (1) | PL194245B1 (cs) |
| PT (1) | PT1000063E (cs) |
| RU (1) | RU2197490C2 (cs) |
| SI (1) | SI1000063T1 (cs) |
| SK (1) | SK283075B6 (cs) |
| TR (1) | TR200000278T2 (cs) |
| TW (1) | TW506971B (cs) |
| UA (1) | UA57088C2 (cs) |
| WO (1) | WO1999006406A1 (cs) |
| ZA (1) | ZA986786B (cs) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2788696B1 (fr) * | 1999-01-26 | 2004-03-05 | Synthelabo | Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central |
| FR2788776B1 (fr) | 1999-01-26 | 2001-02-23 | Synthelabo | Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique |
| GB0000564D0 (en) * | 2000-01-11 | 2000-03-01 | Merck Sharp & Dohme | Therapeutic agents |
| FR2811990A1 (fr) * | 2000-07-24 | 2002-01-25 | Sanofi Synthelabo | DERIVES DE 1-(4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1 -CARBONYL)PIPERAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| FR2811897A1 (fr) * | 2000-07-24 | 2002-01-25 | Sanofi Synthelabo | UTILISATION DE DERIVES DE PYRIDAZINO[4,5-b]INDOLE-1- ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AU TRAITEMENT DES DYSFONCTIONNEMENTS DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES |
| FR2833953B1 (fr) * | 2001-12-21 | 2004-12-03 | Sanofi Synthelabo | DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO [4,5-b]INDOLE-1-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| FR2838124B1 (fr) * | 2002-04-03 | 2004-05-28 | Sanofi Synthelabo | Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique |
| EP1824820A2 (en) * | 2004-12-07 | 2007-08-29 | Janssen Pharmaceutica N.V. | Substituted tetracyclic tetrahydrofuran,pyrrolidine and tetrahydrothiophene derivatives |
| RU2409352C2 (ru) * | 2005-05-05 | 2011-01-20 | САНОФИ-АВЕНТИС Ю.Эс. ЭлЭлСи | Стабильные составы наночастиц |
| KR20080061354A (ko) * | 2005-08-29 | 2008-07-02 | 사노피-아벤티스 유.에스. 엘엘씨 | 7-클로로-Ｎ,Ｎ,5-트리메틸-4-옥소-3-페닐-3,5-디히드로-4Ｈ-피리다지노[4,5-ｂ]인돌-1-아세트아미드의 무정형 고체분산체 |
| JP5063600B2 (ja) * | 2005-08-29 | 2012-10-31 | サノフイ−アベンテイス・ユー・エス・エルエルシー | ピリダジノ［４，５−ｂ］インドール誘導体の新規な結晶形 |
| MX2008004024A (es) * | 2005-09-23 | 2009-02-27 | Schering Corp | Antagonistas de receptor de glutamato metabotropico-1 tetraciclicos fusionados como agentes terapeuticos. |
| CN1946120B (zh) * | 2006-10-20 | 2010-05-12 | 华为技术有限公司 | 实现话单关联的方法及系统 |
| CN102186854A (zh) * | 2008-08-18 | 2011-09-14 | 赛诺菲-安万特美国有限责任公司 | 制备7-氯-N，N，5-三甲基-4-氧代-3-苯基-3，5-二氢-4H-哒嗪并[4，5-b]吲哚-1-乙酰胺的多晶型的方法 |
| EP2181717A1 (en) | 2008-10-28 | 2010-05-05 | Sanofi-Aventis | Use of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-B]indole-1-acetamide as a biomarker of peripheral benzodiazepine receptor levels |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4985560A (en) * | 1990-01-12 | 1991-01-15 | American Home Products Corporation | Pyridazino(4,5-b)indolizines |
| FI94531C (fi) * | 1990-03-13 | 1995-09-25 | Ime Intermed Enterpris Sa | Menetelmä farmaseuttisesti aktiivisen 1,3,4,6,7,8-heksahydro-2H-pyrimido-(1,2-a)-pyrimidiinijohdannaisen valmistamiseksi |
| GB9411955D0 (en) * | 1994-06-15 | 1994-08-03 | Merck Sharp & Dohme | Therapeutic agents |
| US5756501A (en) * | 1995-12-13 | 1998-05-26 | American Home Products Corporation | Saturated and unsaturated pyridazino 4,5-B! indolizines useful as antidementia agents |
| FR2754262B1 (fr) * | 1996-10-08 | 1998-10-30 | Synthelabo | Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique |
-
1997
- 1997-07-30 FR FR9709692A patent/FR2766823B1/fr not_active Expired - Fee Related
-
1998
- 1998-07-28 US US09/463,634 patent/US6262045B1/en not_active Expired - Lifetime
- 1998-07-28 UA UA99127213A patent/UA57088C2/uk unknown
- 1998-07-28 PL PL98338445A patent/PL194245B1/pl not_active IP Right Cessation
- 1998-07-28 RU RU2000102672/04A patent/RU2197490C2/ru not_active IP Right Cessation
- 1998-07-28 EE EEP200000056A patent/EE04317B1/xx not_active IP Right Cessation
- 1998-07-28 CZ CZ2000320A patent/CZ290011B6/cs not_active IP Right Cessation
- 1998-07-28 SI SI9830309T patent/SI1000063T1/xx unknown
- 1998-07-28 WO PCT/FR1998/001667 patent/WO1999006406A1/fr active IP Right Grant
- 1998-07-28 JP JP2000505164A patent/JP4322421B2/ja not_active Expired - Fee Related
- 1998-07-28 SK SK129-2000A patent/SK283075B6/sk not_active IP Right Cessation
- 1998-07-28 AT AT98941468T patent/ATE226584T1/de active
- 1998-07-28 EP EP98941468A patent/EP1000063B1/fr not_active Expired - Lifetime
- 1998-07-28 CA CA002298522A patent/CA2298522C/en not_active Expired - Fee Related
- 1998-07-28 KR KR10-2000-7000935A patent/KR100497782B1/ko not_active Expired - Fee Related
- 1998-07-28 DE DE69808921T patent/DE69808921T2/de not_active Expired - Lifetime
- 1998-07-28 IL IL13363398A patent/IL133633A/en active IP Right Grant
- 1998-07-28 NZ NZ502361A patent/NZ502361A/en not_active IP Right Cessation
- 1998-07-28 HU HU0002650A patent/HU229430B1/hu not_active IP Right Cessation
- 1998-07-28 AU AU89832/98A patent/AU736600B2/en not_active Ceased
- 1998-07-28 PT PT98941468T patent/PT1000063E/pt unknown
- 1998-07-28 CN CNB988076071A patent/CN1134440C/zh not_active Expired - Fee Related
- 1998-07-28 ES ES98941468T patent/ES2186212T3/es not_active Expired - Lifetime
- 1998-07-28 BR BRPI9811582-0A patent/BR9811582B1/pt not_active IP Right Cessation
- 1998-07-28 TR TR2000/00278T patent/TR200000278T2/xx unknown
- 1998-07-28 DK DK98941468T patent/DK1000063T3/da active
- 1998-07-29 AR ARP980103713A patent/AR013264A1/es active IP Right Grant
- 1998-07-29 TW TW087112458A patent/TW506971B/zh not_active IP Right Cessation
- 1998-07-29 CO CO98043191A patent/CO5210883A1/es active IP Right Grant
- 1998-07-29 ZA ZA986786A patent/ZA986786B/xx unknown
-
2000
- 2000-01-20 BG BG104096A patent/BG64283B1/bg unknown
- 2000-01-28 NO NO20000462A patent/NO313963B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK283075B6 (sk) | Deriváty 4-oxo-3,5-dihydro-4H-pyridazino[4,5-b]indol-1-acetamidu a farmaceutický prostriedok, ktorý ich obsahuje | |
| PL191489B1 (pl) | Pochodna 2-arylo-8-oksodihydropuryny, sposób jej wytwarzania i jej zastosowanie, zawierająca ją kompozycja farmaceutyczna, zawierający ją środek do leczenia oraz zawierający ją środek przeciwlękowy | |
| CZ20002691A3 (cs) | Triazolopyridazinové deriváty | |
| US6075021A (en) | 1H-pyrido[3,4-b]indole-4-carboxamide derivatives, preparation and application thereof in therapeutics | |
| EA004373B1 (ru) | 1-АМИНОТРИАЗОЛО[4,3-a]ХИНАЗОЛИН-5-ОНЫ И/ИЛИ -5-ТИОНЫ, ИНГИБИРУЮЩИЕ ФОСФОДИЭСТЕРАЗУ IV | |
| EP1377583A1 (en) | Novel tricyclic hydroxy carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists | |
| US5512590A (en) | 5,6-dihydro-4h-imidazo 2',1':2,3!imidazo- 4,5,1-ij!quinoline and 4,5-dihydroimidazo- 1,2-a!pyrolo 1,2,3-cd!benzimidazole derivatives, their preparation and application in therapeutics | |
| SK4694A3 (en) | 9h-imidazo (1,2,-a) benzimidazole-3-acetamide derivatives method of their preparation and pharmaceutical compounds containing these derivatives | |
| FI63405B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara imdazo(1,5-a)(1,4)diazepin-foereningar | |
| MXPA00001009A (en) | 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b | |
| HK1028027B (en) | 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b)-indole-1-acetamide derivatives, their preparation and their application in therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20140728 |